Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors

    NEXT STORY
    AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
    PREV STORY
    Annual Financial Report
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Crop Protection Chemicals Market Report (2019-2024) by Product Type, Origin, Crop Type, Form, Mode of Application, and Region

    author_avatar
    NASDAQ Market News

    Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera®) to FDA

    SAINT-GENIS-POUILLY, France, July 27, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA ...

    author_avatar
    NASDAQ Market News

    Precision Therapeutics Forms Scientific Advisory Board to Advance its Strategy in the Precision Medicine Sector

    Marc Malandro PhD Named First Member of Scientific Advisory BoardMINNEAPOLIS , Sept. 06, 2018 ...

    author_avatar
    NASDAQ Market News